Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

News SummaryMost relevantAll newsSector newsTweets

NABI BIOPM : Nabi Biopharmaceuticals Announces Second Quarter 2011 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
08/03/2011 | 10:40pm CEST

ROCKVILLE, Md., Aug 3, 2011 (GlobeNewswire via COMTEX) --

Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its second quarter financial results for the three month period ended June 25, 2011. The Company reported a net loss of $4.6 million, or $0.11 per share, compared to a net loss of $3.4 million, or $0.08 per share, for the period ended June 26, 2010.

Second quarter revenue was $3.7 million reflecting $3.2 million recognized from the initial payments received from GlaxoSmithKline Biologicals (GSK) associated with the PentaStaph(TM) sale and NicVAX(R) option and license agreements and $0.5 million for services provided to GSK under the PentaStaph and NicVAX agreements. Revenue for the second quarter 2010 was $4.8 million and included $3.9 million recognized from the initial PentaStaph and NicVAX payments and $0.9 million for services provided under the PentaStaph and NicVAX agreements.

Research and Development expenses were $6.5 million in the second quarter of 2011 compared to $6.5 million in 2010. Research and development expenses are expected to decline over the remainder of 2011 compared to 2010 levels. General and Administrative expenses were $1.4 million for the quarter ended June 25, 2011 compared to $1.2 million in the prior year period. General and administrative for the balance of 2011 will decrease slightly compared to 2010 levels.

For the six months ended June 25, 2011, the Company's net loss was $2.6 million, or $0.06 cents per share, compared to net income of $2.1 million, or $0.04 cents per share, for the six months ended June 26, 2010. Revenue of $12.9 million was recognized for the six months ended June 25, 2011 compared to $18.6 million for the comparable 2010 period. Research and development expenses were $11.8 million for the current six-month period compared to $12.4 million for the 2010 period while general and administrative expenses for the current six-month period were $2.8 million compared to $3.0 million in 2010.

Net cash used in operating activities was $9.0 million for the first six months of 2011 compared to net cash provided by operating activities of $40.4 million in the first six months of 2010. This change is primarily due to a reduction in the level of payments received from GSK associated with the PentaStaph and NicVAX agreements. Cash, cash equivalents and marketable securities totaled $102.3 million at June 25, 2011 compared to $110.7 million at the end of 2010. The decrease resulted from net cash used in operations.

The company did not repurchase any shares of common stock during the first half of 2011. Since inception of the stock repurchase plan in December 2007, we have repurchased a total of 19.9 million shares for a total of $87.2 million. A balance of $27.8 million remains available in the plan for future share repurchases.

Recent and Upcoming Events

  --  In April 2011, received the $5 million payment for the final PentaStaph
      milestone which was achieved in the first quarter of 2011.
  --  In April 2011, the FDA approved Phoslyra, which is a new liquid
      formulation of PhosLo. Under an agreement with Fresenius USA
      Manufacturing, Inc. who owns the product, Nabi is entitled to a $5
      million milestone payment upon the first commercial sale of this product
      and up to $65 million in royalties from incremental annual sales through
  --  In July 2011, reported that the first NicVAX phase III clinical trial
      failed to meet its primary endpoint.
  --  Expect results from the second NicVAX Phase III trial by the end of 2011
      or early 2012

"We were surprised and disappointed with the results of the first Phase III trial of NicVAX. We continue to analyze the data from the trial with an objective to determine the reasons for the unexpected results. This data and the results of the second Phase III trial will help us determine the appropriate actions to take. Meanwhile, we continue our effort to reduce operating costs while the board of directors considers any and all strategic options for the company," said Dr. Raafat Fahim, President and Chief Executive Officer of Nabi Biopharmaceuticals.

Financial Results Conference Call and Webcast Information

The Company will host a live webcast at 4:30 p.m. EDT today to discuss these results. The live webcast can be accessed at:


Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your browser. Remove the space if one exists. The webcast may also be accessed via the Nabi Biopharmaceuticals website at http://www.nabi.com.

If you do not have Internet access, the U.S./Canada call-in number is 866-783-2142 and the international call-in number is 857-350-1601. The passcode is 86701508. An audio replay will be available through August 10, 2011 for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 91000473.

The press release and an archived version of the webcast will be available on the company's website at http://www.nabi.com.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the area of nicotine addiction. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to conduct and obtain successful results from our two Phase III clinical trials for NicVAX of which the first of two Phase III clinical trials failed to meet its primary endpoint; GSK's failure to exercise its option for and successfully commercialize NicVAX; GSK's failure to successfully develop and commercialize any future generation candidate nicotine vaccine; our ability to commercialize NicVAX if GSK does not exercise its option for NicVAX; our ability to identify an alternative partner or to raise sufficient new capital resources to fully develop and commercialize NicVAX if GSK does not exercise the NicVAX option; our ability to successfully contract with and obtain manufactured NicVAX product from contract manufacturing organizations; our ability to attract, retain and motivate key employees; our ability to collect any further milestones and royalty payments under the PhosLo agreement; the ability to obtain regulatory approval for NicVAX and any future generation candidate nicotine vaccine in the U.S. or other markets; our ability to comply with reporting and payment obligations under government rebate and pricing programs; and loss of full use of our net operating loss carry forwards. Some of these factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 25, 2010 filed with the Securities and Exchange Commission. We do not undertake to update any of these forward-looking statements or to announce the results of any revisions to these forward-looking statements except as required by law.

               Nabi Biopharmaceuticals
                    (In thousands)

                               June 25,      25,

                                 2011        2010
                              ----------  ----------
  Current assets:
   Cash and cash equivalents    $ 86,618    $ 53,564
   Marketable securities          15,706      54,603
   Receivables                       726       1,030
   Prepaid expenses and
    other current assets           1,873         829
                              ----------  ----------
     Total current assets        104,923     110,026

  Marketable securities               --       2,500
  Property and equipment,
   net                               295         597

  Other assets                       121         748
                              ----------  ----------

  Total assets                 $ 105,339   $ 113,871
                              ==========  ==========

  Current liabilities:
   Accounts payable              $ 1,189       $ 552
   Accrued expenses and
    other current
    liabilities                    5,615       7,377
   Deferred revenue                2,526       7,797
   Liabilities of
    discontinued operations        2,207       2,207
                              ----------  ----------
     Total current
      liabilities                 11,537      17,933

  Deferred revenue                34,106      35,368
                              ----------  ----------
  Total liabilities               45,643      53,301

  Stockholders' equity:
   Convertible preferred
    stock                             --          --
   Common stock                    6,355       6,321
   Capital in excess of par
    value                        372,071     370,366
   Treasury stock               (92,567)    (92,567)
   Other comprehensive
    income (loss)                      3         (3)

   Accumulated deficit         (226,166)   (223,547)
                              ----------  ----------
     Total stockholders'
      equity                      59,696      60,570
                              ----------  ----------
  Total liabilities and
   stockholders' equity        $ 105,339   $ 113,871
                              ==========  ==========

                              Nabi Biopharmaceuticals
                     (In thousands, except per share amounts)

                                     For the Three Months    For the Six Months
                                             Ended                  Ended
                                    ----------------------  ---------------------
                                     June 25,    June 26,    June 25,    June 26,

                                       2011        2010        2011        2010
                                    ----------  ----------  ----------  ---------

   Revenue                             $ 3,744     $ 4,849    $ 12,917   $ 18,590
  Operating expenses:
   Costs of services                       549         615       1,174      1,285
   Research and development
    expenses                             6,456       6,525      11,791     12,435
   General and administrative
    expenses                             1,426       1,196       2,768      2,965
                                    ----------  ----------  ----------  ---------
  Operating income (loss)              (4,687)     (3,487)     (2,816)      1,905
   Interest income                          50          67         122         91
   Interest expense                         --        (45)          --      (187)

   Other income (expense), net              38          59          75        265
                                    ----------  ----------  ----------  ---------

  Net income (loss)                  $ (4,599)   $ (3,406)   $ (2,619)    $ 2,074
                                    ==========  ==========  ==========  =========

  Basic income (loss) per share       $ (0.11)    $ (0.08)    $ (0.06)     $ 0.04
  Diluted income (loss) per share     $ (0.11)    $ (0.08)    $ (0.06)     $ 0.04

  Basic weighted average shares
   outstanding                          42,307      44,377      42,221     46,456
  Diluted weighted average shares
   outstanding                          42,307      44,377      42,221     46,691

                           Nabi Biopharmaceuticals
                               (In thousands)

                                                      For the Six Months
                                                      June 25,    June 26,

                                                        2011        2010
                                                     ----------  ---------

  Cash flow from operating activities:
   Net income (loss) from continuing operations       $ (2,619)    $ 2,074
   Adjustments to reconcile net income (loss) from continuing operations
    to net
   cash provided by (used in) operating activities from continuing
     Depreciation and amortization                          110        220
     Accretion of discount on convertible senior
      notes                                                  --         99
     Share-based compensation                             1,215      1,102
     Loss (gain) on sale of property and equipment           29        (4)
   Changes in assets and liabilities:
     Receivables                                            304      4,538
     Prepaid expenses and other assets                    (417)        240
     Accounts payable, accrued expenses and other
      liabilities                                       (1,119)      1,509

     Deferred revenue                                   (6,534)     31,252
                                                     ----------  ---------
  Net cash provided by (used in) operating
   activities from continuing operations                (9,031)     41,030
  Net cash used in operating activities from
   discontinued operations                                   --      (609)
                                                     ----------  ---------
  Net cash provided by (used in) operating
   activities                                           (9,031)     40,421
                                                     ----------  ---------

  Cash flow from investing activities:
   Proceeds from sales and maturities of marketable
    securities                                           52,035     64,516
   Purchases of marketable securities                  (10,632)   (90,560)
   Proceeds from sales of property and equipment            158         50

   Capital expenditures                                     (1)        (2)
                                                     ----------  ---------
  Net cash provided by (used in) investing
   activities                                            41,560   (25,996)
                                                     ----------  ---------

  Cash flow from financing activities:
   Proceeds from issuances of common stock for
    employee benefit plans                                  525        412
   Purchase of common stock for treasury                     --   (35,843)

   Repurchase of convertible senior notes                    --    (6,050)
                                                     ----------  ---------
  Net cash provided by (used in) financing
   activities                                               525   (41,481)
                                                     ----------  ---------

  Net increase (decrease) in cash and cash
   equivalents                                           33,054   (27,056)

  Cash and cash equivalents at beginning of period       53,564     59,510
                                                     ----------  ---------

  Cash and cash equivalents at end of period           $ 86,618   $ 32,454
                                                     ==========  =========

This news release was distributed by GlobeNewswire, www.globenewswire.

SOURCE: Nabi Biopharmaceuticals

CONTACT:  Investor Relations
share with twitter share with LinkedIn share with facebook
share via e-mail
08/16 AVIRAGEN THERAPEUTICS : Biotech Stock Performance Review -- Aralez Pharma, Arena..
07/04 BANCO LATINOAMERICANO DE COMERCI EXT : BLX) Analysts See $0.69 EPS, Shorts at Av..
05/08 AVIRAGEN THERAPEUTICS, INC. : Management's Discussion and Analysis of Financial ..
05/04 AVIRAGEN THERAPEUTICS, INC. (NASDAQ : AVIR) Files An 8-K Results of Operations a..
05/04 AVIRAGEN THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
05/04 Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Result..
04/05 AVIRAGEN THERAPEUTICS INC : Blog Coverage Aviragen to Explore Strategic Alternat..
04/04 AVIRAGEN THERAPEUTICS (NASDAQ : AVIR) Files An 8-K Departure of Directors or Cer..
04/04 AVIRAGEN THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other E..
04/04 Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides..
More news
Financials ($)
Sales 2017 8,43 M
EBIT 2017 -30,2 M
Net income 2017 -31,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 2,73x
Capi. / Sales 2018 4,19x
Capitalization 23,0 M
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Average target price 4,17 $
Spread / Average Target 599%
EPS Revisions
Joseph M. Patti President, CEO & Executive Director
Russell H. Plumb Executive Chairman
Mark P. Colonnese Chief Financial Officer & Executive Vice President
Anna Novotney-Barry Vice President-Clinical Development
John H. Vernachio Vice President-Preclinical Development
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN14.42%122 067